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1. Introduction 
Androgenic-anabolic steroid hormones (AAS) are synthetic derivatives of the male hormone 
testosterone and for many years have been popular among athletes both for performance 
enhancement, due to physiological and psychological effects, and for aesthetic reasons 
(Evans 2004; Hartgens & Kuipers 2004). The anabolic action of AAS is particularly 
interesting since its affects protein metabolism by stimulation of protein synthesis and 
inhibition of protein breakdown, which could induce muscle growth and enhance 
adaptation to resistance training (Yesalis & Bahrke 1995; Brown et al. 2006). Since the AAS 
use in sport is banned, different nutritional strategies have been developed in the past 
decades to circumvent this problem and administer other exogenous testosterone analogues 
(King et al. 1999).  
In the past 2o years, different steroid prohormones or prosteroids (e.g. androstenedion, 
dehydroepiandrosterone, androstenediol, 19-nor androstenediol, 19-nor androstenedione, 1-
testosterone) have been developed and aggressively marketed in athletic environment as 
legal nutritional supplements that are expected to convert to active anabolic steroid 
hormones in the body and enhance exercise performance (Brown et al. 1999; Brown et al. 
2000; Earnest et al. 2000; Leder et al. 2000; Brown et al. 2001; Kanayama et al. 2001). The 
efficacy and safety of these prohormones are not well established but are highly promoted 
to have the same androgenic effects on building muscle mass and strength as AAS (Baulieu 
et al. 2000; Brown et al. 2006). A typical steroid prohormone is intended to be a precursor to 
both testosterone and estrogens, through different biochemical pathways (Figure 1), 
typically resulting in the action of dehydrogenases in skeletal muscle, adipose tissue, skin, 
prostate and adrenal gland (Griffin 2004).  
Dehydroepiandrosterone (3β-hydrohy-5-androsten-17-one; DHEA) seems to be the master 
steroid prohormone due its precursor function and its conversion to other hormones (Brown 
et al. 2006). Although the mechanism of action of DHEA or other prosteroids is not 
completely understood, it could be hypothesized that DHEA could increase testosterone 
production (at least as an acute response) if supplemented in diet, and due to its anabolic 
action may affects nitrogen balance and protein synthesis (Morales et al. 1998).  
Testosterone is synthesized through either the Δ-4 or Δ-5 pathway (Broeder 2003) with the 
effects of newly synthesized testosterone in humans occur by way of 2 main mechanisms: by 
activation of the androgen receptor (directly or as 5α-dihydrotestosterone), and by 
conversion to estradiol and activation of estrogen receptors (Wilson 1988). Free testosterone 
www.intechopen.com
 
Steroids – Clinical Aspect 
 
12
 
Fig. 1. Androgens biosynthesis from cholesterol to testosterone/dihydrotestosterone and 
estrogens (estrone and estradiol) via prohormone precursors (e.g. DHEA, androstenedione, 
androstenediol). Abb. DHEA – dehydroepiandrosterone. 
is transported into the cytoplasm of target tissue cells, where it can bind to the androgen 
receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5-
alpha reductase (Hartgens & Kuipers 2004). DHT binds to the same androgen receptor even 
more strongly than testosterone, so that its androgenic potency is about 5 times that of 
testosterone (Breiner et al. 1986). The testosterone-receptor or DHT-receptor complex 
undergoes a structural change that allows it to move into the cell nucleus and bind directly 
to specific nucleotide sequences of the chromosomal desoxiribonucleic acid. The areas of 
binding are called hormone response elements, and influence transcriptional activity of 
certain genes, producing the anabolic effects (Saartok et al. 1984). Theoretically, the fewer 
interconversion steps a prohormone must complete in the syntheisis pathway to 
testosterone, the greater potential for enhancing active hormone production (Broeder 2003); 
for example, androstenedione converts to testosterone more rapidly than DHEA.  
Existing data suggest that acute oral ingestion of DHEA, androstenediol or androstenedione 
modestly and transiently increase serum testosterone concentration; however, this is 
accompanied by greater increase in other steroids as well (i.e. estrogens, luteinizing 
hormone) (Ziegenfuss et al. 2002). Yet, it is questionable if this acute elevation in 
testosterone concentration induced by prosteroids necessarily result in enhanced 
transcriptional activity (Broeder 2003). Furthermore, research has shown that prosteroids 
may have significant biological activity by itself (Ostojic et al. 2009, Ostojic et al. 2010), 
affecting resting metabolic rate through futile cycling (Tagliaferro et al. 1986), increasing the 
flux of fatty acids through β-oxidation (Mohan et al. 1988), and alter the level of serotonin 
and dopamine (Cleary 1991; Ebeling et al. 1994; Kroboth 1999). Yet, the mechanism of action 
of prosteroids may differ between compounds because of variations in the steroid molecules 
(Hartgens & Kuipers 2004). These differences could be responsible for differences in the 
specificity of binding to receptor proteins or to interactions with various steroid-
metabolizing enzymes (Wilson 1988; Creutzberg & Schols 1998) with future research needed 
to clarify the explaining physiological effects due to prosteroids use in humans. 
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2. History of steroid prohormones use in sport and exercise 
Although the first documented reports of misuse of AAS by athletes stem from the 1950s 
(Yesalis 1999), the use of prosteroids in the athletic environment is rather new. Prosteroids 
were indirectly introduced with US Anabolic Steroid Control Act of 1990 (21 USCS Section 
802), which defined anabolic steroids as “…any drug or hormonal substance that promotes 
muscle growth in a manner physiologically similar to testosterone…”, while steroid prohormones 
were not classified as anabolic steroids and could be purchased legally as dietary 
supplements (Broeder 2003; Brown et al. 2006). This document didn’t appear to make a 
significant decrease in the use of anabolic steroids (Brainum 2008), but concern about the 
side effects linked to steroid use did lead to the development of another popular anabolic 
offering: prohormone nutritional supplements (Brown et al. 2003).  
In December of 1996, androstenedione became available for over-the-counter sales in United 
States (Ziegenfuss et al. 2002), with subsequent availability of several other prohormones 
(e.g. androstenediol, DHEA, norandrostenedione). The non-critical promotion era of 
prosteroids in sport began with the disclosure of androstenedione use by Mark McGwire in 
1998, who at the time was elite baseball player, which stimulated extensive media attention 
and dramatically increased the sales of prohormones among recreative and professional 
athletes (Brown et al. 2003, Brown et al. 2006).  
In the past decades, prohormones have been highly marketed in the field of sport as lean 
body mass builders, fat reduction agents, and anticatabolic compounds. Recently, concerns 
over the safety of the prohormones use induced changes in US Anabolic Steroid Control Act 
in 2004 (21 USCS Section 802, amended), redefining anabolic steroids and classify 
prohormones as controlled substances. While the 2004 amendment specifically mentioned 
most of the current prohormones by name, that didn’t stop some companies from marketing 
at least one anabolic steroid that the lawmakers had overlooked (Brainum 2008).  
At the moment, it seems that legal status of prohormones is different throughout the world. 
In USA, Canada or Australia prosteroids are recognized as controlled substances and it is 
illegal to own or sell the product without prescription. On the other hand, no prescription is 
required for prosteroids purchase in several European countries, Russia or Japan, with 
products recognized as over-the-counter dietary supplements.   
3. Epidemiology of steroids use among athletes: scope of the problem 
Anabolic steroid usage has been recognized as a serious health and ethical problem among 
athletes for several decades (Foster & Housner 2004). Numerous examples of steroid usage 
rules violations have been highly publicized and have lead to the suspension and stripping 
of medals from international athletes, as well as many professional athletes (International 
Olympic Committee 1997; Wroble et al. 2002). Elite athletes are not the only population of 
individuals that use steroids. Recreational athletes also use steroids to enhance performance 
and to improve personal appearance (Wroble et al. 2002). Furthermore, evidence indicates 
that steroid usage often starts during high school (Yesalis et al, 1989; Kerr and Congeni 
2007). Use of anabolic steroids is widespread in the athletic environment, particularly in 
power events and disciplines (e.g. football, track and field, body building, power lifting) 
(Foster & Housner 2004).  
It seems that athletes have used AAS for more than 50 years, with first anecdotal evidence of 
use of animal testicular extracts even in 1890s (Yesalis 1999). Despite educational and 
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preventive measures, steroid use increases (Windsor & Dumitru 1988). The prevalence of 
AAS abuse has been reported in several populations. The highest estimates have come from 
male bodybuilders with even more than 50% regularly using steroids (Tricker et al. 1989; 
Lindstrom et al. 1990). Lower rates have been reported among intercollegiate athletes, 
ranging from 15% to 20% (Dezelsky et al. 1985). Rates of steroids use vary greatly across 
individual sports and are used in higher frequency and higher doses by strength athletes 
(Sturmi & Diorio 1998). By contrast, only 1% of their nonathletic university student 
counterparts reported steroids use (Dezelsky et al. 1985). Perhaps the most surprising and 
alarming finding is the rather high rate of steroids abuse among high school students 
(Mulcahey et al. 2010). The typical rate reported in male students is between 5% and 6%, but 
rates as high as 11% have been reported (Johnson et al 1989). The most recent estimate 
reported a range of 5% to 15% for steroids use among high school boys. In female high 
school students, steroids abuse rates tend to be lower, but quite worrisome at 1% to 3% 
(Harmer 2010). Wroble and co-workers (2002) indicated that less than one percent (0.7%) of 
youth sports participants reported current or previous usage of anabolic steroids; the rate of 
usage was higher in males than females. Three percent of athletes had been offered steroids 
at some time with 22% of them admitted to using steroids. Of the reported anabolic steroid 
users, 27% admitted they used anabolic steroids for athletic performance; 18% used to 
improve personal appearance; 18% used for bodybuilding; and 18% took due to peer 
pressure. Twelve percent of all athletes said that they personally know someone who was 
using or had used steroids.  
Although several prohormones are considered as AAS, and are banned by many sports 
governing bodies, including the International Olympic Committee (IOC), they are semi-legal 
substances available from many retail outlets, including internet health food stores. The 
overall prevalence of prohormones use is not known, although several reports indicated that 
prohormones are among the most popular dietary supplements especially in adolescent 
athletes (Smurawa & Congeni 2007). Even though usage has decreased by over 50% since 
1989, steroid use in sport is still a serious problem. Insufficient knowledge and 
inappropriate attitudes regarding the benefits and risks of using anabolic steroids is also a 
major concern (Schwingel et al. 2011). 
4. Testosterone production and musculotrophic effects of prosteroids 
The most prevalent reason for athletes initiating AAS or prosteroids use is to promote 
muscle mass and strength (Yen et al. 1995). From long list of previous studies (for review see 
Hartgens & Kuipers 2004) it could be concluded that steroids administration may increase 
muscle mass. Exogenous testosterone administration (> 125 mg/week), with and without 
strength training program, may lead to increments of muscle volume and/or muscle fibre 
size. Yet, lower doses of testosterone (e.g. 25, 50 or 100 mg/week) had no effect on muscle 
fibre cross-sectional area. It seems that musculotrophic effect of steroids is dose-dependent. 
Therefore, the effects of prosteroids on muscle size and/or strength is highly influenced by 
its potential to increase serum testosterone after administration.  
Existing data on testosterone-boosting effects of prosteroids are equivocal; it seems that age 
and basal serum testosterone concentration may influence the response to prosteroids intake 
(Brown et al. 2000). Several studies reported that serum sex steroid levels in both mature 
and young men were not significantly affected by prohormone supplementation, with only 
a minimal amount converted to testosterone and more to estrogen (Vogiatzi et al. 1996; 
www.intechopen.com
 
Steroid Prohormones: Effects on Body Composition in Athletes 
 
15 
Morales et al. 1998; Kroboth et al. 1999; Yamada et al. 2007). No changes in levels of 
testosterone and estradiol were observed for men after supplementation with 50 mg of 
DHEA for 3, 6 and 12 months (Von Muhlen et al. 2008). In 19 young men (23 ± 1 yr old) 
participating in an 8-week resistance training, ingestion of 150 mg/day of DHEA did not 
affect serum testosterone and estrogen concentrations (Bowers 1999). On the other hand, 
ingesting 100 mg of androstenedione t.i.d. for 28 days increases serum-free testosterone 
concentration by 40% (Brown et al. 2000; Brown et al. 2001), while 200 mg of 
androstenediione increases testosterone area under the curve by approximately 15% during 
the 90 min post-administration (Earnest et al. 2000). In recent study (Ostojic et al. 2010) 
intake of DHEA resulted in significant increase of total testosterone in treated subjects after 
28-days of supplementation. Accordingly, Wolf et al. (1997) reported 1.3-fold increase in 
testosterone levels after supplementation with 50 mg oral DHEA for 2 weeks in 25 men. 
Furthermore, serum estradiol levels were significantly elevated, indicating that a significant 
portion of the ingested prosteroids underwent aromatization. It seems that both the 
magnitude of the dose administered and the route of administration affect the extent of 
change in concentrations of sex hormones (Ziegenfuss et al. 2002). Furthermore, several 
studies confirm the importance of extraadrenal and extragonadal 3ß-hydroxysterodi 
dehydrogenase activity in the synthesis of androgens and estrogens after prohormones 
administration (Nestler et al. 1991; Kroboth et al. 1999).  
Not all subjects respond to prohormones in same fashion, suggesting that additional factors 
(i.e. age, gender, diet, type and intensity of exercise) influence these responses. For example, 
research demonstrates that prohormone supplementation may acutely increase testosterone 
levels in women, thus producing a virilizing effect (Bahrke & Yesalis 2004). Furthermore, 
exercise could result in increased DHEA and DHEA-S concentrations (Bernton et al. 1995) 
and these elevated levels in athletes could influence response to supplementation, which 
requires further investigation. The recent study (Ostojic et al. 2010) reported an increase of 
total testosterone and estradiol while free testosterone is normal. These data can be 
consistent with an increase of sex hormone binding globulin (SHBG) by prosteroids 
administration (Nestler et al. 1991). Total testosterone was increased to keep normal free 
testosterone or in alternative free testosterone was normal due to an increase activation of 5-
alpha reductase. Measuring SHBG luteinizing and folicle-stimulating hormone in future 
studies should prove these hypotheses. However, it is important to point out that simply 
producing an acute elevation in a particular hormone concentration (i.e. testosterone) does 
not necessarily result in increases in muscle mass or lean body mass. Prosteroids do not 
appear to have functional benefits when taken in daily concentrations up to 300 mg per day 
in young, middle-aged or older men (Wallace et akl. 1999; Ballantyne et al. 2000; Broeder 
2003). Although oral DHEA intake enhanced testosterone production for 30%, Ostojic and 
co-workers (2010) did not found changes in total muscle mass or regional muscularity.  
It seems that effect of prosteroids on serum hormones was not mediated by an effect on 
body composition. Increasing DHEA or other prohormones levels may not provide the 
optimal anabolic environment desired in spite of elevated total testosterone level, due to 
several possible mechanisms (i.e. genetic polymorphism of the androgen receptor, potential 
hormonal interconversions at the paracrine level) (Nestler et al. 1991). Whether the increase 
of testosterone after intake of prohormones translates into a meaningful change in body 
composition or rates of muscle protein synthesis is debatable. Studies must be evaluated in 
terms of the relative potency of various testosterone enhancers with varying effects on 
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different tissues according to receptor-binding properties of the compound and its 
metabolites (Ebeling & Koivisto 1994). The relative potency of prosteroids seems to be small 
with inconsiderable advantageous anabolic properties. Several authors hypothesized that an 
important part of the musculotrophic effect of prosteroids may not be directly mediated 
through androgen receptors but instead involves interference with catabolic effects 
produced by glucocorticoid hormones binding to their specific receptors (Bernton et al. 1995; 
Morales et al. 1998). With an incomplete understanding of how prohormones exert their 
effects on skeletal muscle, further studies should analyze nitrogen balance indicators as 
noninvasive approximate index of muscle protein status.  
5. Fat mass alteration and steroid prohormones intake   
In the field of sports and exercise nutrition, prosteroids (DHEA in particular) are often 
promoted as fat-burning agent that could enhance body physique and estetize appearance 
(Kroboth et al. 1999). However, clear evidence supporting the use of prosteroids in athletic 
environment remains less clear. It is well known that age-related decreases in DHEA are 
associated with increases in obesity and a decline in fat free mass (Morales et al. 1998) yet 
the potential usefulness of DHEA as a slimming agent is mostly indicated by previous 
research in animals, particularly lower mammals (Cleary 1991). In the rat plasma 
concentration of DHEA ranges between 14 and 80 nM while in the plasma of humans 
DHEA-concentration ranges between 5 and 24 nM and DHEAS-concentration is up to 9 μM 
(Svec & Porter 1998).  The anti-obesity effect of DHEA in animals could be due to several 
possible mechanisms (Cleary 1991; Ebeling & Koivisto 1994; Kroboth et al. 1999). However, 
studies that have investigated the effects of oral prosteroids supplementation on body 
composition in humans produced equivocal results, particularly in young men.  
Nestler et al. (1988) reported that 28-day supplementation with DHEA (1600 mg/day) 
reduced body fat by 31% with no change in body mass in five normal men. Serum total 
testosterone, free testosterone, sex hormone-binding globulin, estradiol, and estrone levels 
did not change while serum DHEA-S and androstenedione rose 2.0- to 3.5-fold in DHEA 
group. Morales et al. (1998) founded that 100 mg of DHEA for 6 months induced decrease in 
body fat mass (6.1 ± 2.6%) in healthy non-obese men. On the other side, several investigators 
showed that body composition was not affected by prosteroids treatment in young and 
adult men, both obese and non-obese (Usiskin et al. 1990; Welle et al. 1990; Wallace et al. 
1999). Vogiatzi et al. (1996) suggested that DHEA 40 mg administered sublingually twice 
daily for 8 weeks has no positive effects on body composition in obese young adults. In 
recent DAWN trial (Von Muhlen et al. 2008) no beneficial effects of 50 mg daily oral DHEA 
supplementation on body composition were found in 110 healthy mature men. In 
accordance with above research, the recent study (Ostojic et al. 2010) failed to show any 
beneficial effects of oral DHEA administration on body mass and body composition in non-
obese young athletes. Authors did not found significant reduction in body fat of young 
soccer players after DHEA supplementation. Other indicators of body fatness (i.e. body 
mass index, waist-to-hip ratio) remained unchanged during the study in both DHEA and 
placebo group, indicating that treatment with DHEA does not result in significant changes 
to justify its use as an antiobesity or slimming agent. As in the case of cognition, negative 
results in healthy volunteers can be attributed either to a true lack of DHEA effect or to body 
composition too close to ideal at the study start to detect changes in the small numbers of 
subjects studied.  
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Although most studies found no beneficial effects of prosteroids supplementation on body 
composition in athletes, several investigators underlined possible beneficial effects of 
prosteroids supplementation for elderly. Hernandez-Morante et al. (2008) demonstrated for 
the first time in vitro that DHEA-S stimulates lipolysis in 85 obese patients, preferably in 
subcutaneous fat in women and in visceral fat in men. A study by Ho et al. (2008) suggested 
that low DHEA-S is associated with increased waist-to-hip ratio and reduced insulin 
sensitivity with aging while Hsu et al. (2008) had reported that body composition and 
insulin sensitivity can change with aging in early lifetime. Benefits of prosteroids 
supplementation in this regard for early middle-aged people requires more clinical 
investigation.  
Although the body composition changes induced by steroids or prosteroids administration 
are rather small, after the drug withdrawal the alterations of body composition fade away in 
slow manner, but may be presented in part for period up to 3 months (Kuipers et al. 1991; 
Hartgens et al. 2001; Brown et al. 2006). Yet, the final net results of short-term steroids or 
prosteroids administration on body composition seems to be minute (Hartgens & Kuipers 
2004). This is particularly true for all athletes who are not capable of maintaining the 
nutritional intake and training workload of the level required for significant body 
composition changes (Hartgens et al. 1996). It may be important that steroid cessation is 
followed by a period of hypogonadism, while testicular function gradually returns to 
normal, over a period of weeks or several months (Hartgens & Kuipers 2004). Although this 
has not been specifically studied, reduced circulating androgen during this period may help 
to accelerate the loss of any anabolic steroid-induced gains. How much of the gain can be 
sustained by physical training following drug cessation remains to be studied (Yesalis & 
Bahrke 2000). 
6. Known and potential health risks of prosteroids administration 
During the past 20 years, researches suggested that potential risk factors associated with 
prosteroids use were similar to those observed with anabolic steroids (Broeder 2002). The 
altered hormonal milieu caused by prohormone intake is similar to the hormonal milieu 
observed in men with gynecomastia, prostate cancer, testicular cancer and pancreatic cancer 
(Fyssas et al. 1997; Chang et al. 2005). Yet, no documented cases exist of these endocrine-
related diseases caused by prohormone supplementation (Brown et al. 2006). Furthermore, it 
seems that athletes who regularly use prosteroids experienced several side effects (e.g. 
fatigue, headache, nasal congestion, acne, increased aggressiveness, increased blood 
pressure, masculinization in women, gynecomastia and testicular wasting in men) (Broeder 
et al. 2000). Although prohormones induces small decreases in high-density lipoprotein 
cholesterol (HDL-C), long-term implications of transient negative changes in blood lipids 
(e.g. 3-6 mg/dL reductions in HDL-C) have yet to be elucidated as the risk of sustaining a 
cardiac event (Ziegenfuss et al. 2002).  
Regarding unfavourable body composition changes, it has been noted that prohormones 
could lead to changes in hydration of the fat free mass (via sodium and water retention), 
which could be interpreted as hyperhydration effect (Casaburi et al. 1996). Whether more 
prolonged (> 8-12 weeks) prohormones supplementation is safe or useful remains uncertain, 
but appears unlikely (Ziegenfuss et al. 2002). Although some health risks have been noted, 
thus far none of the prohormones tested appear to be overly toxic as no elevations in 
clinically relevant tissue enzymes (e.g. alanine aminotransferase, creatine kinase, aspartate 
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aminotransferase, gamma-glutamyltransferase, lactate dehydrogenase) have been observed 
(Brown et al. 2000; Ziegenfuss et al. 2002). However, due to the lack of efficacy of oral 
prosteroids supplementation in athletes, its theoretical risks seem to fat outweight any 
potential benefits on body composition and should be discouraged (Earnest 2001).  
7. Summary 
In the past 2o years, different steroid prohormones or prosteroids have been aggressively 
marketed in athletic environment as legal nutritional supplements that are expected to 
convert to active anabolic steroid hormones in the body and enhance exercise performance. 
Although the mechanism of action of prosteroids is not completely understood it has been 
promoted that prosteroids increases testosterone production if supplemented in diet and 
due to its anabolic action may affects nitrogen balance and protein synthesis. Although 
popular among athletes, studies have demonstrated repeatedly that acute and long-term 
administration of these oral testosterone precursors does not effectively increase serum 
testosterone levels and fails to produce any significant changes in lean body mass, muscle 
strength, or performance improvement compared with placebo. It seems that increasing 
prohormone levels in athletes may not provide the optimal anabolic environment desired in 
spite of elevated total testosterone level (at least acutely), due to several possible 
mechanisms (i.e. genetic polymorphism of the androgen receptor, potential hormonal 
interconversions at the paracrine level). The relative potency of prosteroids seems to be 
small with inconsiderable advantageous anabolic properties. Furthermore, recent studies 
indicates that treatment with prosteroids does not result in significant changes to justify its 
use as an antiobesity or slimming agent. Not all subjects respond to prohormones in same 
fashion, suggesting that additional factors (i.e. gender, diet, type and intensity of exercise) 
influence these responses. Although some health risks have been noted, thus far none of the 
prohormones tested appear to be overly toxic. Yet, due to the lack of efficacy of oral 
prosteroids supplementation in athletes, its theoretical risks seem to far outweight any 
potential benefits on body composition and should be discouraged. Although the 
understanding of testosterone precursors as performance-enhancing drugs continues to 
advance, there are likely to be more revelations as scientific investigations continue. 
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